OA10.03 How LungMATCH, A Personalized Treatment Navigation and Clinical Trial Matching Service, Affects the Treatment Journey

Introduction: GO2 Foundation for Lung Cancer developed the LungMATCH program in response to the unmet need of truly personalized, free, and unlimited treatment navigation and clinical trial matching. The program gives patients and caregivers access to information pertaining to their specific type of lung cancer ranging from biomarker test interpretation and acquisition to interpretation of the medical science pertaining to their next line of treatment and nation-wide clinical trial searches and matching in addition to free educational materials in the forms of one pagers, brochures, and a quarterly educational newsletter. The program seeks to determine if empowering patients and caregivers with these resources affects the treatment journey. Methods: Data was collected as patient reported biomarker testing, history of all treatments received, and clinical trial participation through phone or email contact from 2018-2020. Data was interpreted and transformed using mean values to account for longitudinal consistency. Repeat patients or caregiver contacts were treated as separate and individual data points. Clinical trial accrual rates were measured only taking into account patients or caregivers who identified clinical trials as a potential treatment option. Results: As the years progressed, patients and caregivers reported increased usage of precision medicine as measured by targeted and immuno- therapy usage and biomarker testing rates (Table). Additionally, clinical trial accrual rates remained higher than the national average and increased each year (Table. Increased participation since program launch, despite the impact of the COVID-19 pandemic, suggests a positive impact of the service on a patient’s treatment journey. [Formula presented] Conclusion: LungMATCH has been able to show that empowering patients with personalized information about their lung cancer correlates withhigh rates of biomarker testing, personalized medicine, and clinical trial accrual. It is important to highlight the success of LungMATCH in maintaining higher than national average clinical trial accrual rates and the identified best practices on how to increase accrual year over year. Preliminary data about reason for contact combined with the high percentage of patients who know the result of their biomarker testing, suggest LungMATCH could have a direct positive impact on patient education and empowerment in regards to their testing. Future directions of LungMATCH include analysis of quality of care as measured by NCCN guidelines and the identification of correlative practices that may point to NCCN guideline care. Keywords: Clinical trials, Patient advocacy, precision medicine